MPR

MPR Associates Mourns the Passing of Dr. Douglas M. Chapin, Former Principal Officer

Retrieved on: 
Dienstag, Mai 7, 2024
Engineering, Other Energy, Manufacturing, Alternative Energy, Energy, Nuclear, Naval Reactors, National academy, Void coefficient, State, News, Safety, NR-1, Research, Hyman G. Rickover, Navy, MPR, Admiral, Culture, Nuclear energy, Friends, American Nuclear Society, Principal, Natural environment, Renewable energy

MPR Associates Inc., is deeply saddened to share the news of the passing of Dr. Douglas M. Chapin, esteemed and admired former Principal Officer of MPR where his career spanned five decades.

Key Points: 
  • MPR Associates Inc., is deeply saddened to share the news of the passing of Dr. Douglas M. Chapin, esteemed and admired former Principal Officer of MPR where his career spanned five decades.
  • Dr. Chapin’s nuclear career started in 1962 as an officer in the US Navy Nuclear Propulsion Program.
  • In addition to his achievements at MPR, Dr. Chapin was deeply committed to serving the broader scientific and engineering communities.
  • “MPR would not be what MPR is today without the contributions and leadership of Doug Chapin,” Bob Coward, MPR Principal Officer said.

77% of Workers Think Companies Want Employees Back in the Office To Gain Greater Control Over Them: MyPerfectResume Report

Retrieved on: 
Montag, März 25, 2024
Workplace, Pressure, MPR, Communication

GUAYNABO, Puerto Rico, March 25, 2024 /PRNewswire-PRWeb/ -- MyPerfectResume® (MPR), a leading resource for resume and career advice, has announced findings from its 2024 Return to Office Survey, indicating workers' sentiment around return-to-office (RTO) policies, current pressure from management to work on-site, and how other workplace benefits compare against remote work policies. The survey sought to better understand how RTO is currently impacting the workplace.

Key Points: 
  • About one in three (28%) say that their company has threatened to fire employees who don't comply with RTO policies.
  • Which perks, including unlimited PTO, a four-day work week, and health benefits, could entice them back to full-time onsite work.
  • However, even extremely valuable perks and benefits aren't enough to entice most workers to return to the office.
  • When asked which other benefits would encourage them to return to an office full-time, some fared better than others.

EudraVigilance registration manual

Retrieved on: 
Mittwoch, April 3, 2024
Scroll, University, Data analysis, Patient, Account, Organization, MAH, Medicine, Manual, MFL, IAM, VAT, Finalize (optical discs), QAT, Competence, Documentation, Letter, Privacy, HQ2, ServiceNow, Environment, Trust (social science), RP, Table, Record, MPR, European Medicines Agency, Restricted area, Yahoo!, Identity management, Change request, Access, Qualified person (European Union), HQ, MMD, Home, Hospital, Research, Service, Network affiliate, Comment, Access management, OMS, Send, MSSO, ISO, Commercial, European, NCA, NCS, Managed services, Next, Document, EMA, PSMF, Language, MedDRA, AMP, Database, ICSR, Figure, EudraGMP, Dictionary, AMPS, Reproduction, Quality assurance, Identity, Virtual, Q2, SME, Change, Importance, Management, Security, Name, Location, Sponsor, Completeness, ID, 24 Hours, User, Vaccine
Key Points: 

    Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo in Resectable Non-Small Cell Lung Cancer

    Retrieved on: 
    Mittwoch, Februar 7, 2024
    Science, Biotechnology, Research, Pharmaceutical, Surgery, Oncology, Health, Clinical Trials, Survival, Melanoma, Bristol Myers Squibb, Congress, NSCLC, EFS, PCR, Lung cancer, Patient, FDA, EMA, IIA, BMY, Food, ESMO, European Medicines Agency, Cancer, PDUFA, Bladder cancer, Checkmate, MPR, Pharmaceutical industry

    Bristol Myers Squibb (NYSE: BMY) today announced two regulatory acceptances for applications for neoadjuvant Opdivo (nivolumab) with chemotherapy followed by surgery and adjuvant Opdivo for the perioperative treatment of resectable stage IIA to IIIB non-small cell lung cancer (NSCLC).

    Key Points: 
    • Bristol Myers Squibb (NYSE: BMY) today announced two regulatory acceptances for applications for neoadjuvant Opdivo (nivolumab) with chemotherapy followed by surgery and adjuvant Opdivo for the perioperative treatment of resectable stage IIA to IIIB non-small cell lung cancer (NSCLC).
    • "Between 30% to 55% of non-small cell lung cancer patients who undergo surgery will experience disease recurrence.
    • The study also showed benefits in key secondary endpoints including pathologic complete response (pCR) and major pathologic response (MPR).
    • Opdivo and Opdivo-based combinations have shown efficacy benefits in the neoadjuvant, adjuvant or perioperative settings across four cancers to date, including lung cancer, bladder cancer, esophageal/gastroesophageal junction cancer and melanoma.

    Banco Santander-Chile Announces Fourth Quarter 2023 Earnings

    Retrieved on: 
    Freitag, Februar 2, 2024
    Pillar, BSAC, CHF, Growth, Central bank, ESG, Travel, NPS, Quarter, CLP, Daiwa Securities Group, Acceleration, Column, Government, SME, JPY, Banco Santander, COVID-19, DJSI, Environment, Banco Santander Chile, Investment banking, YTD, NPL, KBRA, Corporation, NII, NIM, S&P Global Ratings, Credit, Bank, Behavior, Moody's Investors Service, Retail banking, Central Bank of Myanmar, CIB, Life, Drainage, RWA, FMC, BIS, ADR, Yoy, Japan Credit Rating Agency, Insurance, MPR, TSR, Cryptocurrency

    SANTIAGO, Chile, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Banco Santander Chile (NYSE: BSAC; SSE: Bsantander) announced today its resultsi for the twelve-month period ended December 31, 2023, and fourth quarter 2023 (4Q23).

    Key Points: 
    • SANTIAGO, Chile, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Banco Santander Chile (NYSE: BSAC; SSE: Bsantander) announced today its resultsi for the twelve-month period ended December 31, 2023, and fourth quarter 2023 (4Q23).
    • As of December 31, 2023 our NPS reached 60 points, and our contact center reached 72 points, being recognized as the best in the industry.
    • Our CET1 ratio remains solid at 11.1% and the total Basel III ratio reaches 17.6% at the end of December 2023.
    • Our earnings webcast will be held on Friday, February 2, 2023 at 8.30am New York time.

    Gus Fonte Elected to Lead Nation's Largest Local Realtor Association

    Retrieved on: 
    Freitag, Februar 2, 2024
    Venus, Mia, SFR, ABR, MRP, Economic development, PMN, YPN, TRC, RCE, CIPS, Business improvement district, University, GRI, City, SRES, CNE, CAE, SRS, Vice, PSA, Policy, CCIM, Coral Gables, Florida, CRS, MPR, Real estate

    MIAMI, Feb. 2, 2024 /PRNewswire-PRWeb/ -- The MIAMI Association of Realtors (MIAMI) installed 2024 MIAMI Chairman of the Board Gus Fonte, CCIM at its Inaugural & Awards Celebration on Feb. 2 at the Seminole Hard Rock Hotel & Casino in Hollywood.

    Key Points: 
    • "As a proud MIAMI member since 1987, I'm honored to lead our incredible association, the largest in the United States"
      "As a proud MIAMI member since 1987, I'm honored to lead our incredible association, the largest in the United States," Fonte said.
    • Let's showcase our Realtor value proposition, continue our industry-leading advocacy efforts and elevate our Realtor education.
    • Fonte has volunteered his time as a MIAMI Association of Realtors leader since 2005, when he led MIAMI Commercial.
    • Born and raised in Miami, Fonte currently lives in Miami with his wife, Maryellen, and has two children, Gus and Mia.

    Electric Vehicle Motor Market to Record Growth of USD 14.49 billion from 2022 to 2027, ABB Ltd. and Allied Motion Technologies Inc. to emerge as Some of the key companies - Technavio

    Retrieved on: 
    Mittwoch, Januar 31, 2024
    IPR, AC, Chevrolet Volt, USD, Transport, Volkswagen, EVS, Hitachi, Toyota Prius, Electric vehicle, Anxiety, Continental AG, Carbon, Ford Motor Company, Hyundai Ioniq, Ametek, Hyundai, HPR, Volkswagen Group, Growth, Mitsubishi Electric, Acceleration, Challenge, Leaf, ABB, COVID-19, Sonata, Toyota, Nissan Leaf, Robert Bosch GmbH, Hyundai Sonata, MPR, Automotive industry

    NEW YORK, Jan. 30, 2024 /PRNewswire/ -- The electric vehicle motor market is estimated to grow by USD 14.49 billion from 2023 to 2027, according to Technavio.

    Key Points: 
    • NEW YORK, Jan. 30, 2024 /PRNewswire/ -- The electric vehicle motor market is estimated to grow by USD 14.49 billion from 2023 to 2027, according to Technavio.
    • Mid-power rating (MPR) motors, like the 80kW MPR motor in the Nissan Leaf, are favored in hybrid and low-range pure electric vehicles.
    • By geography, the global electric vehicle motor market is segmented into APAC, Europe, North America, South America, and the Middle East and Africa.
    • What are the key data covered in this Electric Vehicle Motor Market report?

    InstantGMP Inc. Welcomes Insane Labz to Enhanced Manufacturing Excellence

    Retrieved on: 
    Dienstag, Januar 23, 2024
    Quality management system, MPR, IMS, EBR, CGMP, Documentation, QMS, GMP, Risk, Software, FDA, BPR

    CARY, N.C., Jan. 23, 2024 /PRNewswire-PRWeb/ -- InstantGMP™, the leader in software systems that captures your manufacturing, inventory and quality data, is excited to announce its newest client, Insane Labz®, a renowned nutritional supplement company.

    Key Points: 
    • Derek Mathis, Quality Manager of Insane Labz, shared, "InstantGMP PRO has revolutionized our manufacturing processes.
    • Initially relying on third-party co-packers, Insane Labz established its own manufacturing facility in 2014, demonstrating a commitment to producing high quality products in an FDA registered, cGMP certified facility.
    • InstantGMP PRO provides Insane Labz with an end-to-end integrated manufacturing/inventory/quality system that enables precise control over formulation, ingredient sourcing, manufacturing, testing, and product distribution.
    • Derek Mathis, Quality Manager of Insane Labz, expressed his enthusiasm for this software solution by stating, "InstantGMP PRO has revolutionized our manufacturing processes.

    CBRN Defense Market worth $21.4 billion by 2028 - Exclusive Report by MarketsandMarkets™

    Retrieved on: 
    Montag, Januar 15, 2024
    Electro, Research, GPS, Artificial intelligence, Assistant Secretary for Health, Army, Growth, Personal protective equipment, Rheinmetall, Machine learning, Law enforcement, Police, Bruker, Air force, Software, Natural language, MPR, Chemical warfare, Equipment, Business, Commercial, Explosive, CBRN defense, Investment, Sense, Original equipment manufacturer, Wi-Fi, Natural language processing, Lidar, Navy, Commerce, Airborne, Teledyne Technologies, Thales Group, CBRN, Arms industry

    Based on Type, chemical segment is estimated to witness the largest share of the CBRN Defense market from 2023 to 2028.

    Key Points: 
    • Based on Type, chemical segment is estimated to witness the largest share of the CBRN Defense market from 2023 to 2028.
    • The chemical segment of the CBRN Defense market is estimated to hold the dominant position in the market in 2023.
    • Based on end use, the defense & government segment is estimated to account for the largest share of the CBRN Defense market from 2023 to 2028.
    • The Asia Pacific market is projected to contribute the largest share from 2023 to 2028 in the CBRN Defense market.

    CBRN Defense Market worth $21.4 billion by 2028 - Exclusive Report by MarketsandMarkets™

    Retrieved on: 
    Montag, Januar 15, 2024
    Electro, Research, GPS, Artificial intelligence, Assistant Secretary for Health, Army, Growth, Personal protective equipment, Rheinmetall, Machine learning, Law enforcement, Police, Bruker, Air force, Software, Natural language, MPR, Chemical warfare, Equipment, Business, Commercial, Explosive, CBRN defense, Investment, Sense, Original equipment manufacturer, Wi-Fi, Natural language processing, Lidar, Navy, Commerce, Airborne, Teledyne Technologies, Thales Group, CBRN, Arms industry

    Based on Type, chemical segment is estimated to witness the largest share of the CBRN Defense market from 2023 to 2028.

    Key Points: 
    • Based on Type, chemical segment is estimated to witness the largest share of the CBRN Defense market from 2023 to 2028.
    • The chemical segment of the CBRN Defense market is estimated to hold the dominant position in the market in 2023.
    • Based on end use, the defense & government segment is estimated to account for the largest share of the CBRN Defense market from 2023 to 2028.
    • The Asia Pacific market is projected to contribute the largest share from 2023 to 2028 in the CBRN Defense market.